[Sarcoidosis caused by grains of pepper in a patient with micro-nodular minor tuberculoid leprosy].

A. Bazex,R. Salvador,A. Dupré,B. Christol,P. Vitasse

Abstract:

What problem does this paper attempt to address?

eIF3f Mediates SGOC Pathway Reprogramming by Enhancing Deubiquitinating Activity in Colorectal Cancer

Qihao Pan,Fenghai Yu,Huilin Jin,Peng Zhang,Xiaoling Huang,Jingxuan Peng,Xiaoshan Xie,Xiangli Li,Ning Ma,Yue Wei,Weijie Wen,Jieping Zhang,Boyu Zhang,Hongyan Yu,Yuanxun Xiao,Ran‐yi Liu,Qingxin Liu,Xiangqi Meng,Mong‐Hong Lee

DOI: https://doi.org/10.1002/advs.202300759

IF: 15.1

2023-08-08

Advanced Science

Abstract:Wnt pathways have activities in regulating eIF3f expression via β‐catenin and TCF4 signaling, and eIF3f is overexpressed in CRC. eIF3f acts as a deubiquitinating enzyme regulating PHGDH post‐transcriptionally through EGF‐GSK3β‐FBXW7β axis. Moreover, eIF3f can deubiquitinate and stabilize MYC, thereby regulating PHGDH transcriptionally via MYC. Therefore, targeting eIF3f‐PHGDH axis may be a potential CRC treatment strategy. Numerous studies have demonstrated that individual proteins can moonlight. Eukaryotic Initiation translation factor 3, f subunit (eIF3f) is involved in critical biological functions; however, its role independent of protein translation in regulating colorectal cancer (CRC) is not characterized. Here, it is demonstrated that eIF3f is upregulated in CRC tumor tissues and that both Wnt and EGF signaling pathways are participating in eIF3f's oncogenic impact on targeting phosphoglycerate dehydrogenase (PHGDH) during CRC development. Mechanistically, EGF blocks FBXW7β‐mediated PHGDH ubiquitination through GSK3β deactivation, and eIF3f antagonizes FBXW7β‐mediated PHGDH ubiquitination through its deubiquitinating activity. Additionally, Wnt signals transcriptionally activate the expression of eIF3f, which also exerts its deubiquitinating activity toward MYC, thereby increasing MYC‐mediated PHGDH transcription. Thereby, both impacts allow eIF3f to elevate the expression of PHGDH, enhancing Serine–Glycine–One–Carbon (SGOC) signaling pathway to facilitate CRC development. In summary, the study uncovers the intrinsic role and underlying molecular mechanism of eIF3f in SGOC signaling, providing novel insight into the strategies to target eIF3f‐PHGDH axis in CRC.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
eIF3a Regulates Colorectal Cancer Metastasis via Translational Activation of RhoA and Cdc42

Chao Mei,Chong Liu,Ying Gao,Wen-Ting Dai,Wei Zhang,Xi Li,Zhao-Qian Liu

DOI: https://doi.org/10.3389/fcell.2022.794329

IF: 5.5

2022-03-01

Frontiers in Cell and Developmental Biology

Abstract:Tumor metastasis is the major cause of tumor relapse and cancer-associated mortality in colorectal cancer, leading to poor therapeutic responses and reduced survival. eIF3a was previously described as an oncogene. However, its role in colorectal cancer progression and metastasis has not yet been fully investigated. In this study, the expression specificity and predictive value of eIF3a were investigated in clinical samples. The effects of eIF3a on cell proliferation and migration were verified in vivo and in vitro , respectively. The underlying molecular mechanism was revealed by western blotting, immunofluorescence, RNA-binding protein immunoprecipitation, and dual-luciferase reporter gene assays. The results showed that eIF3a was significantly overexpressed in tumor tissues compared with adjacent normal tissues. High eIF3a expression was correlated with tumor metastasis and overall survival. Downregulation of eIF3a obviously inhibited the proliferation and motility of malignant cells in vitro and in vivo . Mechanistically, eIF3a regulates Cdc42 and RhoA expression at the translation level, which further affects pseudopodia formation and actin cytoskeleton remodeling. Taken together, eIF3a accelerates the acquisition of the migratory phenotype of cancer cells by activating Cdc42 and RhoA expression at the translational level. Our study identified eIF3a as a promising target for inhibiting colorectal cancer metastasis.

cell biology,developmental biology
Translation initiation factor eIF3a regulates glucose metabolism and cell proliferation via promoting small GTPase Rheb synthesis and AMPK activation

Shijie Ma,Zizheng Dong,Yanfei Huang,Jing-Yuan Liu,Jian-Ting Zhang

DOI: https://doi.org/10.1016/j.jbc.2022.102044

IF: 5.485

2022-07-01

Journal of Biological Chemistry

Abstract:Eukaryotic translation initiation factor 3 subunit A (eIF3a), the largest subunit of the eIF3 complex, has been shown to be overexpressed in malignant cancer cells, potentially making it a proto-oncogene. eIF3a overexpression can drive cancer cell proliferation but contributes to better prognosis. While its contribution to prognosis was previously shown to be due to its function in suppressing synthesis of DNA damage repair proteins, it remains unclear how eIF3a regulates cancer cell proliferation. In this study, we show using genetic approaches that eIF3a controls cell proliferation by regulating glucose metabolism via the phosphorylation and activation of AMP-activated protein kinase alpha (AMPKα) at Thr<sup>172</sup> in its kinase activation loop. We demonstrate that eIF3a regulates AMPK activation mainly by controlling synthesis of the small GTPase Rheb, largely independent of the well-known AMPK upstream liver kinase B1 and Ca<sup>2+</sup>/calmodulin-dependent protein kinase kinase 2, and also independent of mammalian target of rapamycin signaling and glucose levels. Our findings suggest that glucose metabolism in and proliferation of cancer cells may be translationally regulated via a novel eIF3a-Rheb-AMPK signaling axis.

biochemistry & molecular biology
eIf3a mediates malignant biological behaviors in colorectal cancer through the PI3K/AKT signaling pathway

Chao Huo,Disheng Wu,Xiaodan Li,Yan Zhang,Baoguang Hu,Taoming Zhang,Jianwei Ren,Tianbao Wang,Yi Liu

DOI: https://doi.org/10.1080/15384047.2024.2355703

2024-05-25

Cancer Biology & Therapy

Abstract:Colorectal cancer (CRC) is among the most common gastrointestinal malignancies worldwide. eIF3a is highly expressed in a variety of cancer types, yet its role in CRC remains unclear. We introduced ectopic eIF3a expression in CRC cells to investigate its relevance to various malignant behaviors. Further, we silenced eIF3a to explore its effect on tumor growth in a nude mouse tumor xenograft model. Finally, the molecular mechanisms through which eIF3a regulates malignancy in CRC cells were explored through bioinformatics analysis combined with the use of a specific PI3K inhibitor (LY294002). eIF3a was highly expressed in the peripheral blood and cancer tissue of CRC patients. Malignancy and tumor growth were significantly inhibited by silencing eIF3a, while overexpression promoted malignant behaviors, with a positive correlation between PI3K/AKT activation and eIF3a expression. Taken together, eIF3a plays an oncogenic role in CRC by regulating PI3K/AKT signaling and is a potential biomarker for CRC diagnosis and prognostic monitoring.

oncology
Eif3a Mediates HIF1α-dependent Glycolytic Metabolism in Hepatocellular Carcinoma Cells Through Translational Regulation.

Bisi Miao,Chuanyuan Wei,Zijun Qiao,Weiyu Han,Xiaoqiang Chai,Jiacheng Lu,Chao Gao,Ruizhao Dong,Dongmei Gao,Cheng Huang,Aiwu Ke,Jian Zhou,Jia Fan,Guoming Shi,Fei Lan,Jiabin Cai

2019-01-01

Abstract:eIF3a is the largest subunit of eIF3 complex and is a key player in translational control. Recently eIF3a is recognized as a proto-oncogene, which is overexpressed and connected to tumorigenesis of many cancers. However, the mechanistic roles of eIF3a during the tumorigenesis remain largely elusive. Here, we report that depletion of eIF3a significantly reduced HIF1α protein level and cellular glycolysis ability. Mechanistically, we found that eIF3a regulates HIF1α protein synthesis through internal ribosomal entry site (IRES)-dependent translation. Importantly, through analyses of our own sample collection, we found that eIF3a is overexpressed in hepatocellular carcinoma (HCC) tissues, and a high level of eIF3a predicts poor prognosis of HCC patients. TCGA analyses further confirmed that eIF3a is coincident with an elevated activity of HIF1α pathway genes. Collectively, we identify eIF3a as a regulator for glycolysis through HIF1α IRES-dependent translational regulation, which may be a potential therapeutic target for HCC.
Eif4ebp3 Was Downregulated by Methylation and Acted As a Tumor Suppressor by Targeting Eif4e/β-Catenin in Gastric Cancer.

Shuting Zhai,Shuang Lin,Zhongjie Lin,Junjie Xu,Tong Ji,Ke Chen,Ke Wu,Hui Liu,Hanning Ying,Weiqiang Fei,Jin Wang,Guoxiang Fu,Yifan Wang,Xiaotong Hu,Xiujun Cai

DOI: https://doi.org/10.1007/s10120-019-01030-x

2019-01-01

Gastric Cancer

Abstract:Epigenetic aberrations of tumor suppressor genes (TSGs), particularly DNA methylation, are frequently involved in the pathogenesis of gastric cancer (GC). Through a methylome study, we identified eIF4EBP3 as a methylated gene in GC. However, the role of eIF4EBP3 in GC progression has not been explored. The expression and promoter region methylation of eIF4EBP3 in GC and healthy tissues were analyzed in public datasets. eIF4EBP3 expression in GC was detected by semi-quantitative RT-PCR, western blot and immunohistochemistry. We also studied epigenetic alterations and functions in GC. The effects of eIF4EBP3 on cell proliferation, migration and invasion were conducted by functional experiments in vitro and in vivo. Label-free proteomic analysis was applied to identify targets of eIF4EBP3. The expression level of eIF4EBP3 was downregulated in gastric cancer due to promoter region methylation, and was associated with poor survival and tumor progression. Ectopic expression of eIF4EBP3 significantly inhibited tumor cell growth, migration and invasion both in vitro and in vivo. Label-free proteomic analysis indicated eIF4EBP3 downregulated the protein level of β-catenin, which was confirmed by western blot. Overexpression of β-catenin reversed the inhibitory effects of eIF4EBP3 on cell growth and migration, indicating that eIF4EBP3 acts on GC cells by targeting the eIF4E/β-catenin axis. These results suggest that eIF4EBP3 is a novel TSG methylated in gastric cancer that may play important roles in GC development and liver metastasis and indicate eIF4EBP3 as a potential metastasis and survival biomarker for GC.
Eukaryotic Translation Initiation Factor 3 and Tumor

Lisha CHU,Xiangyang SONG,Jiang CAO

DOI: https://doi.org/10.3870/j.issn.1672-8009.2010.01.018

2010-01-01

Abstract:The eukaryotic translation initiation factor 3(eIF-3)complex consists of multiple subunits and plays an important role in eukaryotic translation initiation.It has been found in recent years that,various subunits of eIF3 are abnormally express in tumors,which is closely related to tumor invasiveness,metastasis,differentiation,and prognosis of cancer.Therefore,eIF-3 may be hopeful as a potential anti-cancer therapeutic target.
Translational Regulator Eif2α in Tumor

Qinguo Zheng,Jingjia Ye,Jiashu Cao

DOI: https://doi.org/10.1007/s13277-014-1789-0

2014-01-01

Tumor Biology

Abstract:The eukaryotic translation initiation factor 2α (eIF2α) is the regulatory subunit of eIF2 which can be inactivated by phosphorylation. In the adaptive response to various microenvironmental stresses, phosphorylation of eIF2α (p-eIF2α) by specific kinases significantly downregulates global protein synthesis while selectively upregulates the activating transcription factor 4 (ATF4) translation. The ATF4 is a transcription activator that can translocate into nucleus and upregulate genes involved in amino acid synthesis, redox balance, protein maturation, and degradation which lead to the activation of both autophagy and apoptosis. During tumor progression, adaptive response facilitates tumor cell survival and growth under severe stresses. Therefore, eIF2α phosphorylation significantly promotes tumor progression and resistance to therapy. However, there is also evidence showing that p-eIF2α exerts suppressive effects on tumorigenesis. Current understanding of the roles eIF2α plays in tumor is still incomplete and needs further investigation. This review addresses on the past and current efforts to delineate the molecular mechanisms of eIF2α in tumorigenesis, tumor progression, resistance to therapy, and tumor cachexia as well as the translational promise of therapeutic applications targeting eIF2α-related signaling pathway.
EEF1D stabilized by SRSF9 promotes colorectal cancer via enhancing the proliferation and metastasis

Rui Wang,Chi Lv,Donghao Li,Yutong Song,Zhaopeng Yan

DOI: https://doi.org/10.1002/ijc.35039

2024-05-23

International Journal of Cancer

Abstract:What's new? The protein eukaryotic elongation factor 1 delta (EEF1D) plays a role in protein synthesis and is involved in tumor progression in many cancers. Here, the authors investigated expression levels of EEF1D in colorectal cancer (CRC) both in vitro and in vivo using mouse models of CRC. Upregulation of EEF1D accelerated cell proliferation and metastasis, they found, and reducing its levels had the opposite effect. This suggests that EEF1D could be a molecular target for treating CRC. Colorectal cancer (CRC) is the third most common cancer and causes high mortality worldwide. Although CRC has been studied widely, the molecular mechanism is not completely known. Eukaryotic translation elongation factor 1 delta (EEF1D) participates in the progression of various tumors, however, the effect of EEF1D on CRC remains unclear. Here, we aimed to identify the potential mechanism of EEF1D in CRC. The expression levels of EEF1D were assessed in CRC samples. Functional analysis of EEF1D in CRC was detected in vitro and in vivo. The regulatory mechanism of EEF1D was identified with RNA immunoprecipitation, RNA pull‐down assay, and proteomics analysis. Our findings confirmed that EEF1D was upregulated in human CRC tissues. Functionally, EEF1D overexpression accelerated cell proliferation and metastasis, whereas EEF1D knockdown inhibited cell proliferation and metastasis both in vitro and in vivo CRC models. Furthermore, we showed that EEF1D was upregulated by SRSF9 via binding to 3′UTR of EEF1D mRNA. EEF1D knockdown reversed the malignant phenotype induced by SRSF9 overexpression. These findings demonstrated that EEF1D promotes CRC progression, and EEF1D may be a molecular target against CRC.

oncology
eIF3 mRNA selectivity profiling reveals eIF3k as a cancer-relevant regulator of ribosome content

Haoran Duan,Siqiong Zhang,Yoram Zarai,Rupert Öllinger,Yanmeng Wu,Li Sun,Cheng Hu,Yaohui He,Guiyou Tian,Roland Rad,Xiangquan Kong,Yabin Cheng,Tamir Tuller,Dieter A Wolf

DOI: https://doi.org/10.15252/embj.2022112362

2023-06-15

Abstract:eIF3, whose subunits are frequently overexpressed in cancer, regulates mRNA translation from initiation to termination, but mRNA-selective functions of individual subunits remain poorly defined. Using multiomic profiling upon acute depletion of eIF3 subunits, we observed that while eIF3a, b, e, and f markedly differed in their impact on eIF3 holo-complex formation and translation, they were each required for cancer cell proliferation and tumor growth. Remarkably, eIF3k showed the opposite pattern with depletion promoting global translation, cell proliferation, tumor growth, and stress resistance through repressing the synthesis of ribosomal proteins, especially RPS15A. Whereas ectopic expression of RPS15A mimicked the anabolic effects of eIF3k depletion, disruption of eIF3 binding to the 5'-UTR of RSP15A mRNA negated them. eIF3k and eIF3l are selectively downregulated in response to endoplasmic reticulum and oxidative stress. Supported by mathematical modeling, our data uncover eIF3k-l as a mRNA-specific module which, through controlling RPS15A translation, serves as a rheostat of ribosome content, possibly to secure spare translational capacity that can be mobilized during stress.
EIF3i promotes colon oncogenesis by regulating COX-2 protein synthesis and β-catenin activation

J Qi,Z Dong,J Liu,J-T Zhang

DOI: https://doi.org/10.1038/onc.2013.397

IF: 8.756

2013-09-23

Oncogene

Abstract:Translational control of gene expression has recently been recognized as an important mechanism controlling cell proliferation and oncogenesis, and it mainly occurs in the initiation step of protein synthesis that involves multiple eukaryotic initiation factors (eIFs). Many eIFs have been found to have aberrant expression in human tumors and the aberrant expression may contribute to oncogenesis. However, how these previously considered house-keeping proteins are potentially oncogenic remains elusive. In this study, we investigated the expression of eIF3i in human colon cancers, tested its contribution to colon oncogenesis and determined the mechanism of eIF3i action in colon oncogenesis. We found that eIF3i expression was upregulated in both human colon adenocarcinoma and adenoma polyps as well as in model inducible colon tumorigenic cell lines. Overexpression of ectopic eIF3i in intestinal epithelial cells causes oncogenesis by directly upregulating the synthesis of cyclooxygenase-2 (COX-2) protein and activates the β-catenin/T-cell factor 4 signaling pathway that mediates the oncogenic function of eIF3i. Together, we conclude that eIF3i is a proto-oncogene that drives colon oncogenesis by translationally upregulating COX-2 and activating the β-catenin signaling pathway. These findings imply that proto-oncogenic eIFs likely exert their tumorigenic function by regulating/altering the synthesis level of downstream tumor suppressor or oncogenes.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
eIF3a regulation of mTOR signaling and translational control via HuR in cellular response to DNA damage

Shijie Ma,Zizheng Dong,Yanfei Huang,Jing-Yuan Liu,Jian-Ting Zhang

DOI: https://doi.org/10.1038/s41388-022-02262-5

IF: 8.756

2022-03-12

Oncogene

Abstract:eIF3a (eukaryotic translation initiation factor 3a), a subunit of the eIF3 complex, has been suggested to play a regulatory role in protein synthesis and in cellular response to DNA-damaging treatments. S6K1 is an effector and a mediator of mTOR complex 1 (mTORC1) in regulating protein synthesis and integrating diverse signals into control of cell growth and response to stress. Here, we show that eIF3a regulates S6K1 activity by inhibiting mTORC1 kinase via regulating Raptor synthesis. The regulation of Raptor synthesis is via eIF3a interaction with HuR (human antigen R) and binding of the eIF3a-HuR complex to the 5ʹ-UTR of Raptor mRNA. Furthermore, mTORC1 may mediate eIF3a function in cellular response to cisplatin by regulating synthesis of NER proteins and NER activity. Taken together, we conclude that the mTOR signaling pathway may also be regulated by translational control and mediate eIF3a regulation of cancer cell response to cisplatin by regulating NER protein synthesis.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma

Ting Li,Pei-Shan Hu,Zhixiang Zuo,Jin-Fei Lin,Xingyang Li,Qi-Nian Wu,Zhan-Hong Chen,Zhao-Lei Zeng,Feng Wang,Jian Zheng,Demeng Chen,Bo Li,Tie-Bang Kang,Dan Xie,Dongxin Lin,Huai-Qiang Ju,Rui-Hua Xu

DOI: https://doi.org/10.1186/s12943-019-1038-7

IF: 37.3

2019-06-24

Molecular Cancer

Abstract:BackgroundColorectal carcinoma (CRC) is one of the most common malignant tumors, and its main cause of death is tumor metastasis. RNA N6-methyladenosine (m6A) is an emerging regulatory mechanism for gene expression and methyltransferase-like 3 (METTL3) participates in tumor progression in several cancer types. However, its role in CRC remains unexplored.MethodsWestern blot, quantitative real-time PCR (RT-qPCR) and immunohistochemical (IHC) were used to detect METTL3 expression in cell lines and patient tissues. Methylated RNA immunoprecipitation sequencing (MeRIP-seq) and transcriptomic RNA sequencing (RNA-seq) were used to screen the target genes of METTL3. The biological functions of METTL3 were investigated in vitro and in vivo. RNA pull-down and RNA immunoprecipitation assays were conducted to explore the specific binding of target genes. RNA stability assay was used to detect the half-lives of the downstream genes of METTL3.ResultsUsing TCGA database, higher METTL3 expression was found in CRC metastatic tissues and was associated with a poor prognosis. MeRIP-seq revealed that SRY (sex determining region Y)-box 2 (SOX2) was the downstream gene of METTL3. METTL3 knockdown in CRC cells drastically inhibited cell self-renewal, stem cell frequency and migration in vitro and suppressed CRC tumorigenesis and metastasis in both cell-based models and PDX models. Mechanistically, methylated SOX2 transcripts, specifically the coding sequence (CDS) regions, were subsequently recognized by the specific m6A "reader", insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2), to prevent SOX2 mRNA degradation. Further, SOX2 expression positively correlated with METTL3 and IGF2BP2 in CRC tissues. The combined IHC panel, including "writer", "reader", and "target", exhibited a better prognostic value for CRC patients than any of these components individually.ConclusionsOverall, our study revealed that METTL3, acting as an oncogene, maintained SOX2 expression through an m6A-IGF2BP2-dependent mechanism in CRC cells, and indicated a potential biomarker panel for prognostic prediction in CRC.

oncology,biochemistry & molecular biology
[Surgery of cancer of the pharynx and larynx in general anesthesia (color film)].

A. Montandon

1953-10-01

Abstract:
EIF3B is associated with poor outcomes in gastric cancer patients and promotes cancer progression via the PI3K/AKT/mTOR signaling pathway.

Lin Wang,Xianzi Wen,Fengming Luan,Tao Fu,Chao Gao,Hong Du,Ting Guo,Jing Han,Longtao Huangfu,Xiaojing Cheng,Jiafu Ji

DOI: https://doi.org/10.2147/CMAR.S207834

2019-01-01

Cancer Management and Research

Abstract:Purpose: Eukaryotic translation initiation factor (EIF) plays a vital role in protein synthesis. EIF3B is a core subunit of the EIF3 family, and is overexpressed in many tumors. EIF3B is associated with an unfavorable prognosis, as well as the genesis and development of tumors. However, the potential role of EIF3B in gastric cancer (GC) remains unknown. In the current study, we explored the clinical significance and the possible mechanism of EIF3B in the progression of GC. Methods: EIF3B expression was analyzed in 78 GC tissue samples through quantitative PCR and in 94 GC tissue samples through immunohistochemistry (IHC) staining. The correlation between EIF3B and clinicopathological features was analyzed in GC tissues. The role of EIF3B in GC progression was investigated through in vitro and in vivo assays. Results: EIF3B expression was upregulated in GC tissues (73.4%, IHC). High expression of EIF3B was significantly correlated with the depth of tumor invasion, lymph node metastasis and TNM stage (P=0.000, 0.000 and 0.000, respectively). Multivariate analysis indicated that GC patients with high EIF3B expression suffered a poorer 5-year survival. EIF3B promoted GC cell proliferation and was strongly associated with proliferating cell nuclear antigen (PCNA) expression in GC samples (P=0.009). It also enhanced tumor cell migration and invasion, which were affected through epithelial-mesenchymal transition (EMT) and the Stat3 signaling pathway. Knockdown of EIF3B in GC cells suppressed the growth of xenograft tumors and lung metastatic colonization in vivo. Furthermore, gene set enrichment analysis (GSEA) and Western blot results demonstrated that EIF3B activated the PI3K/AKT/mTOR signaling pathway. Conclusion: Our results suggest that EIF3B plays an oncogenic role in GC progression and serves as an independent prognostic factor for GC patients.
N6-methyladenosine Methyltransferase METTL3 Promotes Colorectal Cancer Cell Proliferation Through Enhancing MYC Expression.

Song Xiang,Xiaolong Liang,Shuo Yin,Jian Liu,Zheng Xiang

2020-01-01

Abstract:N6-methyladenosine (m6A) modification is the most common chemical modification in eukaryotic mRNA, which plays a crucial role in regulating mRNA stability, splicing, and translation. METTL3 (methyltransferase like 3), a major RNA N6-adenosine methyltransferase, has been reported to participate in the progression of many cancers. However, its function in colorectal cancer (CRC) remains largely unknown. In this study, we revealed that METTL3 played an oncogenic role in CRC. We found that METTL3 was significantly upregulated in CRC, using quantitative real-time PCR, western blotting, and immunohistochemical staining, and upregulation of METTL3 was associated with clinicopathological features. Functionally, knockdown of METTL3 suppressed CRC cell proliferation in vitro and in vivo. In contrast, overexpression of METTL3 promoted the growth of CRC cells both in vitro and in vivo. Mechanistically, METTL3 exerted its function through enhancing MYC expression, at least partially in an m6A-IGF2BP1-dependent manner. In conclusion, we found that METTL3 was frequently upregulated in human CRC and promoted CRC progression though enhancing MYC expression. This provided new insights into the molecular mechanisms underlying the development of colorectal cancer.
CDK13 phosphorylates the translation machinery and promotes tumorigenic protein synthesis

Chao Wu,Ting Xie,Ying Guo,Donghai Wang,Min Qiu,Ruyi Han,Guoliang Qing,Kaiwei Liang,Hudan Liu

DOI: https://doi.org/10.1038/s41388-023-02653-2

IF: 8.756

2023-03-08

Oncogene

Abstract:Cyclin-dependent kinase 13 (CDK13) has been suggested to phosphorylate RNA polymerase II and is involved in transcriptional activation. However, whether CDK13 catalyzes other protein substrates and how CDK13 contributes to tumorigenesis remain largely unclear. We here identify key translation machinery components, 4E-BP1 and eIF4B, as novel CDK13 substrates. CDK13 directly phosphorylates 4E-BP1 at Thr46 and eIF4B at Ser422; genetically or pharmacologically inhibiting CDK13 disrupts mRNA translation. Polysome profiling analysis shows that MYC oncoprotein synthesis strictly depends on CDK13-regulated translation in colorectal cancer (CRC), and CDK13 is required for CRC cell proliferation. As mTORC1 is implicated in 4E-BP1 and eIF4B phosphorylation, inactivation of CDK13 in combination with the mTORC1 inhibitor rapamycin further dephosphorylates 4E-BP1 and eIF4B and blocks protein synthesis. As a result, dual inhibition of CDK13 and mTORC1 induces more profound tumor cell death. These findings clarify the pro-tumorigenic role of CDK13 by direct phosphorylation of translation initiation factors and enhancing protein synthesis. Therefore, therapeutic targeting of CDK13 alone or in combination with rapamycin may pave a new way for cancer treatment.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
Electromyography in biomechanics.

Gary L Soderberg,Thomas M. Cook

DOI: https://doi.org/10.1093/PTJ/64.12.1813

1984-12-01

Physical Therapy

Abstract:The purpose of this paper is to discuss the use of EMG as related to biomechanical function and dysfunction. The uses and limitations of this technique are described and instrumentation features and methods of data collection and interpretation are presented. We also discuss factors that influence the relationship of EMG to biomechanical measurements and cite as examples studies that have used EMG. Emphasis is placed on improving the ability of the physical therapist to use and interpret EMG data in kinesiology and biomechanics.
Eif6 Promotes Colorectal Cancer Proliferation and Invasion by Regulating AKT-Related Signaling Pathways.

Jinxin Lin,Xihu Yu,Liping Xie,Puning Wang,Tuoyang Li,Yuanlv Xiao,Jiaming Zhou,Shaoyong Peng,Jun Huang,Yanxin Luo,Meijin Huang,Jianping Wang

DOI: https://doi.org/10.1166/jbn.2019.2792

2019-01-01

Journal of Biomedical Nanotechnology

Abstract:Although abnormal expression of eukaryotic initiation factor 6 (eIF6) has been found in several human solid tumors, the functions and underlying mechanisms of eIF6 in the progression of colorectal cancer (CRC) still needs further elucidation. In the present study, large-scale gene analysis based on Oncomine and The Cancer Genome Atlas (TCGA) database revealed significantly higher baseline expression of eIF6 in colorectal cancer than in normal tissues. Furthermore, our Chinese cohort study revealed that high expression of eIF6 was correlated with aggressive characteristics and poor survival in CRC patients. Functional studies using magnetic nanoparticle extraction indicated that eIF6 was an oncogene in CRC cells. Regarding its mechanism, through Gene ontology (GO) and KEGG pathway analysis based on TCGA RNAseq database, we found that eIF6 can activate multiple AKT-related cancer signaling pathways, such as p-AKT\MMP1\cyclinD1\Bcl2-related signaling, to regulate cell proliferation, invasion, cell cycle and apoptosis in CRC. Collectively, these findings suggested that eIF6 can positively regulate AKT-related cancer signaling and enhance tumorigenicity in CRC, and may serve as a potential prognostic indicator and therapeutic target in CRC.
IGF2BP3 Promotes the Progression of Colorectal Cancer and Mediates Cetuximab Resistance by Stabilizing EGFR Mrna in an M6a-Dependent Manner

Li-Jie Chen,Hui-Ye Liu,Zhi-Yuan Xiao,Ting Qiu,Dan Zhang,Ling-Jie Zhang,Fang-Yi Han,Guo-Jun Chen,Xue-Mei Xu,Jiong-Hua Zhu,Yan-Qing Ding,Shu-Yang Wang,Ya-Ping Ye,Hong-Li Jiao

DOI: https://doi.org/10.1038/s41419-023-06099-y

2023-01-01

Abstract:Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), an RNA-binding protein, is associated with tumorigenesis and progression. However, the exact molecular mechanisms of IGF2BP3 in colorectal cancer (CRC) oncogenesis, progression, and drug resistance remain unclear. This study found that IGF2BP3 was upregulated in CRC tissues. Clinically, the elevated IGF2BP3 level is predictive of a poor prognosis. Functionally, IGF2BP3 enhances CRC tumorigenesis and progression both in vitro and in vivo. Mechanistically, IGF2BP3 promotes epidermal growth factor receptor (EGFR) mRNA stability and translation and further activates the EGFR pathway by serving as a reader in an N6-methyladenosine (m6A)-dependent manner by cooperating with METTL14. Furthermore, IGF2BP3 increases the drug resistance of CRC cells to the EGFR-targeted antibody cetuximab. Taken together, our results demonstrated that IGF2BP3 was a functional and clinical oncogene of CRC. Targeting IGF2BP3 and m6A modification may therefore offer rational therapeutic targets for patients with CRC.

[Sarcoidosis caused by grains of pepper in a patient with micro-nodular minor tuberculoid leprosy].

eIF3f Mediates SGOC Pathway Reprogramming by Enhancing Deubiquitinating Activity in Colorectal Cancer

eIF3a Regulates Colorectal Cancer Metastasis via Translational Activation of RhoA and Cdc42

Translation initiation factor eIF3a regulates glucose metabolism and cell proliferation via promoting small GTPase Rheb synthesis and AMPK activation

eIf3a mediates malignant biological behaviors in colorectal cancer through the PI3K/AKT signaling pathway

Eif3a Mediates HIF1α-dependent Glycolytic Metabolism in Hepatocellular Carcinoma Cells Through Translational Regulation.

Eif4ebp3 Was Downregulated by Methylation and Acted As a Tumor Suppressor by Targeting Eif4e/β-Catenin in Gastric Cancer.

Eukaryotic Translation Initiation Factor 3 and Tumor

Translational Regulator Eif2α in Tumor

EEF1D stabilized by SRSF9 promotes colorectal cancer via enhancing the proliferation and metastasis

eIF3 mRNA selectivity profiling reveals eIF3k as a cancer-relevant regulator of ribosome content

EIF3i promotes colon oncogenesis by regulating COX-2 protein synthesis and β-catenin activation

eIF3a regulation of mTOR signaling and translational control via HuR in cellular response to DNA damage

METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma

[Surgery of cancer of the pharynx and larynx in general anesthesia (color film)].

EIF3B is associated with poor outcomes in gastric cancer patients and promotes cancer progression via the PI3K/AKT/mTOR signaling pathway.

N6-methyladenosine Methyltransferase METTL3 Promotes Colorectal Cancer Cell Proliferation Through Enhancing MYC Expression.

CDK13 phosphorylates the translation machinery and promotes tumorigenic protein synthesis

Electromyography in biomechanics.

Eif6 Promotes Colorectal Cancer Proliferation and Invasion by Regulating AKT-Related Signaling Pathways.

IGF2BP3 Promotes the Progression of Colorectal Cancer and Mediates Cetuximab Resistance by Stabilizing EGFR Mrna in an M6a-Dependent Manner